Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 11;8(6):e70900.
doi: 10.1002/hsr2.70900. eCollection 2025 Jun.

Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study

Daisuke Kanda  1 , Akihiro Tokushige  1 , Kenta Ohmure  1 , Daichi Fukumoto  1 , Hirokazu Shimono  1 , Hiroyuki Tabata  1 , Nobuhiro Ito  1 , Takuro Kubozono  1 , Mitsuru Ohishi  1
Affiliations

Impact of Angiotensin-Converting Enzyme Inhibitor on Coronary Artery Calcification Evaluated by Intravascular Ultrasound: A Retrospective Cohort Study

Daisuke Kanda et al. Health Sci Rep. .

Abstract

Background and aims: Coronary artery calcification (CAC) is a predictor of poor prognosis after percutaneous coronary intervention (PCI), and its treatment depends on calcification severity assessed by intravascular imaging such as intravascular ultrasound (IVUS). We aimed to investigate the factors associated with CAC severity and clinical outcomes, with a particular focus on the potential impact of angiotensin-converting enzyme inhibitor (ACEI) use.

Methods: We retrospectively analyzed 630 patients with stable coronary artery disease who underwent IVUS-guided PCI between January 2018 and March 2023. Calcification severity was assessed using IVUS, and patients were grouped into moderate/severe and none/mild calcification. Outcomes included all-cause death and major adverse cardiovascular and cerebrovascular events (MACCEs).

Results: Patients with moderate/severe calcification had a significantly lower survival rate and a higher incidence of MACCEs (p = 0.02 and p < 0.001, respectively). Similarly, patients with calcified nodules had worse outcomes (p = 0.005 and p < 0.001, respectively). ACEI use was independently associated with reduced odds of moderate/severe calcification [OR: 0.56, 95% confidence intervals (CI): 0.36-0.90, p = 0.02] and calcified nodules (OR: 0.10, 95% CI: 0.01-0.74, p = 0.02). In patients with moderate/severe calcification, ACEI use was associated with a lower MACCE rate (p = 0.04).

Conclusion: IVUS-assessed moderate/severe calcification is a strong predictor of all-cause death and MACCE in patients with CAD undergoing PCI. ACEI use was associated with less severe calcification and a lower incidence of MACCE in these patients. Evaluation of calcification may help identify high-risk patients and guide anti-calcification treatment strategies.

Keywords: angiotensin‐converting enzyme inhibitor; calcified nodule; coronary calcification; intravascular ultrasound; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Comparison of Kaplan–Meier survival rates (A) and cumulative incidences of MACCEs (B) after PCI between the moderate/severe and none/mild calcification groups. Abbreviations: MACCEs, major cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention.
Figure 2
Figure 2
Kaplan–Meier analysis of survival rate (A) and cumulative incidences of MACCEs (B) after PCI in the groups with and without calcified nodule lesions. Abbreviations: MACCEs, major cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention.
Figure 3
Figure 3
Kaplan–Meier analysis of cumulative incidences of MACCEs after PCI in the groups with and without ACEI use: (A) none/mild calcification group, (B) moderate/severe calcification group. ACEI, angiotensin‐converting enzyme inhibitor; MACCEs, major cardiovascular and cerebrovascular events; PCI, percutaneous coronary intervention.
See this image and copyright information in PMC

References

    1. Yang S., Zeng Z., Yuan Q., et al., “Vascular Calcification: From the Perspective of Crosstalk,” Molecular Biomedicine 4, no. 1 (2023): 35. - PMC - PubMed
    1. Liu W., Zhang Y., Yu C. M., et al., “Current Understanding of Coronary Artery Calcification,” Journal of Geriatric Cardiology: JGC 12 (2015): 668–675. - PMC - PubMed
    1. Detrano R., Guerci A. D., Carr J. J., et al., “Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups,” New England Journal of Medicine 358, no. 13 (2008): 1336–1345. - PubMed
    1. Lo‐Kioeng‐Shioe M. S., Rijlaarsdam‐Hermsen D., van Domburg R. T., et al., “Prognostic Value of Coronary Artery Calcium Score in Symptomatic Individuals: A Meta‐Analysis of 34,000 Subjects,” International Journal of Cardiology 299 (January 2020): 56–62. - PubMed
    1. Hisamatsu T. and Kinuta M., “Coronary Artery Calcium in Assessment of Atherosclerotic Cardiovascular Disease Risk and Its Role in Primary Prevention,” Journal of Atherosclerosis and Thrombosis 30, no. 10 (2023): 1289–1302. - PMC - PubMed

LinkOut - more resources